ALLO
Price
$1.19
Change
-$0.01 (-0.83%)
Updated
Jul 3 closing price
Capitalization
260.29M
33 days until earnings call
SLDB
Price
$5.03
Change
+$0.16 (+3.29%)
Updated
Jul 3 closing price
Capitalization
389.9M
Interact to see
Advertisement

ALLO vs SLDB

Header iconALLO vs SLDB Comparison
Open Charts ALLO vs SLDBBanner chart's image
Allogene Therapeutics
Price$1.19
Change-$0.01 (-0.83%)
Volume$1.38M
Capitalization260.29M
Solid Biosciences
Price$5.03
Change+$0.16 (+3.29%)
Volume$702.34K
Capitalization389.9M
ALLO vs SLDB Comparison Chart in %
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALLO vs. SLDB commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Hold and SLDB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (ALLO: $1.19 vs. SLDB: $5.03)
Brand notoriety: ALLO and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 42% vs. SLDB: 38%
Market capitalization -- ALLO: $260.29M vs. SLDB: $389.9M
ALLO [@Biotechnology] is valued at $260.29M. SLDB’s [@Biotechnology] market capitalization is $389.9M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileSLDB’s FA Score has 2 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • SLDB’s FA Score: 2 green, 3 red.
According to our system of comparison, SLDB is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 3 TA indicator(s) are bullish while SLDB’s TA Score has 5 bullish TA indicator(s).

  • ALLO’s TA Score: 3 bullish, 6 bearish.
  • SLDB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SLDB is a better buy in the short-term than ALLO.

Price Growth

ALLO (@Biotechnology) experienced а -0.83% price change this week, while SLDB (@Biotechnology) price change was +4.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

ALLO is expected to report earnings on Aug 06, 2025.

SLDB is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLDB($390M) has a higher market cap than ALLO($260M). SLDB YTD gains are higher at: 25.750 vs. ALLO (-44.131). SLDB has higher annual earnings (EBITDA): -136.83M vs. ALLO (-238.37M). SLDB has more cash in the bank: 307M vs. ALLO (280M). SLDB has less debt than ALLO: SLDB (23.6M) vs ALLO (81.3M). ALLO (0) and SLDB (0) have equivalent revenues.
ALLOSLDBALLO / SLDB
Capitalization260M390M67%
EBITDA-238.37M-136.83M174%
Gain YTD-44.13125.750-171%
P/E RatioN/AN/A-
Revenue00-
Total Cash280M307M91%
Total Debt81.3M23.6M344%
FUNDAMENTALS RATINGS
ALLO vs SLDB: Fundamental Ratings
ALLO
SLDB
OUTLOOK RATING
1..100
5512
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
24
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
8739
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (24) in the Biotechnology industry is significantly better than the same rating for ALLO (97). This means that SLDB’s stock grew significantly faster than ALLO’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that SLDB’s stock grew similarly to ALLO’s over the last 12 months.

SLDB's SMR Rating (97) in the Biotechnology industry is in the same range as ALLO (97). This means that SLDB’s stock grew similarly to ALLO’s over the last 12 months.

SLDB's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for ALLO (87). This means that SLDB’s stock grew somewhat faster than ALLO’s over the last 12 months.

SLDB's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for ALLO (100). This means that SLDB’s stock grew significantly faster than ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOSLDB
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 22 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KPTSF6.850.06
+0.83%
KP Tissue Inc
VRTK2.05N/A
N/A
Vartech Systems Inc.
KIROY5.80-0.01
-0.17%
Kumba Iron Ore Ltd.
ARZGY17.63-0.04
-0.23%
Assicurazioni Generali Spa
MRRTY4.12-0.03
-0.60%
Marfrig Global Foods SA